Complement, thrombotic microangiopathy and disseminated intravascular coagulation

Journal of Intensive Care

Volumn 2, Issue 1, 2014, Pages

  Kurosawa, Shinichiro ^a   Stearns Kurosawa, Deborah J ^a  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Acute kidney injury; Blood coagulation; Complement; Disseminated intravascular coagulation; Hemolytic uremic syndrome; Microangiopathic hemolytic anemia; Thrombocytopenia; Thrombotic microangiopathy

Indexed keywords

ACUTE KIDNEY FAILURE; ARTICLE; BLOOD CLOTTING; BRAIN INJURY; CLINICAL PRACTICE; DISSEMINATED INTRAVASCULAR CLOTTING; FIBRINOLYSIS; HEMOLYTIC UREMIC SYNDROME; HUMAN; PRIORITY JOURNAL; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOCYTOPENIA; THROMBOTIC THROMBOCYTOPENIC PURPURA;

EID: 84979198208     PISSN: None     EISSN: 20520492     Source Type: Journal    
DOI: 10.1186/s40560-014-0061-4     Document Type: Article

References (55)

1. Krem MM, Di Cera E. Evolution of enzyme cascades from embryonic development to blood coagulation. Trends Biochem Sci 2002, 27:67-74. 10.1016/S0968-0004(01)02007-2, 11852243.
2. Loof TG, Morgelin M, Johansson L, Oehmcke S, Olin AI, Dickneite G, Norrby-Teglund A, Theopold U, Herwald H. Coagulation, an ancestral serine protease cascade, exerts a novel function in early immune defense. Blood 2011, 118:2589-2598. 10.1182/blood-2011-02-337568, 21613262.
3. Rittirsch D, Flierl MA, Ward PA. Harmful molecular mechanisms in sepsis. Nat Rev Immunol 2008, 8:776-787. 10.1038/nri2402, 2786961, 18802444.
4. Amara U, Rittirsch D, Flierl M, Bruckner U, Klos A, Gebhard F, Lambris JD, Huber-Lang M. Interaction between the coagulation and complement system. Adv Exp Med Biol 2008, 632:71-79. 2713875, 19025115.
5. Oikonomopoulou K, Ricklin D, Ward PA, Lambris JD. Interactions between coagulation and complement-their role in inflammation. Semin Immunopathol 2012, 34:151-165. 10.1007/s00281-011-0280-x, 3372068, 21811895.
6. Liszewski MK, Atkinson JP. Too much of a good thing at the site of tissue injury: the instructive example of the complement system predisposing to thrombotic microangiopathy. Hematol Am Soc Hematol Educ Progr 2011, 2011:9-14.
7. Markiewski MM, Nilsson B, Ekdahl KN, Mollnes TE, Lambris JD. Complement and coagulation: strangers or partners in crime?. Trends Immunol 2007, 28:184-192. 10.1016/j.it.2007.02.006, 17336159.
8. Hamad OA, Back J, Nilsson PH, Nilsson B, Ekdahl KN. Platelets, complement, and contact activation: partners in inflammation and thrombosis. Adv Exp Med Biol 2012, 946:185-205. 10.1007/978-1-4614-0106-3_11, 21948369.
9. Skoglund C, Wettero J, Tengvall P, Bengtsson T. C1q induces a rapid up-regulation of P-selectin and modulates collagen- and collagen-related peptide-triggered activation in human platelets. Immunobiology 2010, 215:987-995. 10.1016/j.imbio.2009.11.004, 20163886.
10. Ikeda K, Nagasawa K, Horiuchi T, Tsuru T, Nishizaka H, Niho Y. C5a induces tissue factor activity on endothelial cells. Thromb Haemost 1997, 77:394-398.
11. Huber-Lang M, Sarma JV, Zetoune FS, Rittirsch D, Neff TA, McGuire SR, Lambris JD, Warner RL, Flierl MA, Hoesel LM, Gebhard F, Younger JG, Drouin SM, Wetsel RA, Ward PA. Generation of C5a in the absence of C3: a new complement activation pathway. Nat Med 2006, 12:682-687. 10.1038/nm1419, 16715088.
12. Ovstebo R, Hellum M, Aass HC, Troseid AM, Brandtzaeg P, Mollnes TE, Henriksson CE. Microparticle-associated tissue factor activity is reduced by inhibition of the complement protein 5 in Neisseria meningitidis-exposed whole blood. Innate Immun 2013, 20:552-560. 10.1177/1753425913502099, 24051102.
13. Chen VM, Hogg PJ. Encryption and decryption of tissue factor. J Thromb Haemost 2013, 11(Suppl 1):277-284. 10.1111/jth.12228, 23809131.
14. Morrissey JH, Choi SH, Smith SA. Polyphosphate: an ancient molecule that links platelets, coagulation, and inflammation. Blood 2012, 119:5972-5979. 10.1182/blood-2012-03-306605, 3383012, 22517894.
15. Amara U, Flierl MA, Rittirsch D, Klos A, Chen H, Acker B, Bruckner UB, Nilsson B, Gebhard F, Lambris JD, Huber-Lang M. Molecular intercommunication between the complement and coagulation systems. J Immunol 2010, 185:5628-5636. 10.4049/jimmunol.0903678, 3123139, 20870944.
16. Kanse SM, Gallenmueller A, Zeerleder S, Stephan F, Rannou O, Denk S, Etscheid M, Lochnit G, Krueger M, Huber-Lang M. Factor VII-activating protease is activated in multiple trauma patients and generates anaphylatoxin C5a. J Immunol 2012, 188:2858-2865. 10.4049/jimmunol.1103029, 22308306.
17. Stavenuiter F, Dienava-Verdoold I, Boon-Spijker MG, Brinkman HJ, Meijer AB, Mertens K. Factor seven activating protease (FSAP): does it activate factor VII?. J Thromb Haemost 2012, 10:859-866. 10.1111/j.1538-7836.2012.04619.x, 22235940.
18. Stephan F, Hazelzet JA, Bulder I, Boermeester MA, van Till JO, van der Poll T, Wuillemin WA, Aarden LA, Zeerleder S. Activation of factor VII-activating protease in human inflammation: a sensor for cell death. Crit Care 2011, 15:R110. 10.1186/cc10131, 3219388, 21466697.
19. Mayer CL, Leibowitz CS, Kurosawa S, Stearns-Kurosawa DJ. Shiga toxins and the pathophysiology of hemolytic uremic syndrome in humans and animals. Toxins, 4(11), 1261-128, 2012. doi:10.3390/toxins4111261. Toxins (Basel) 2012, 4:1261-1287. 10.3390/toxins4111261, 3509707, 23202315.
20. Trofa AF, Ueno-Olsen H, Oiwa R, Yoshikawa M. Dr. Kiyoshi Shiga: discoverer of the dysentery bacillus. Clin Infect Dis 1999, 29:1303-1306. 10.1086/313437, 10524979.
21. Obrig TG. Escherichia coli Shiga toxin mechanisms of action in renal disease. Toxins (Basel) 2010, 2:2769-2794. 10.3390/toxins2122769, 3032420,3032420, 21297888.
22. Copelovitch L, Kaplan BS. Streptococcus pneumoniae-associated hemolytic uremic syndrome. Pediatr Nephrol 2008, 23:1951-1956. 10.1007/s00467-007-0518-y, 17564729.
23. Shimizu M, Yokoyama T, Sakashita N, Sato A, Ueno K, Akita C, Ohta K, Kitano E, Hatanaka M, Kitamura H, Saikawa Y, Yachie A. Thomsen-Friedenreich antigen exposure as a cause of Streptococcus pyogenes-associated hemolytic-uremic syndrome. Clin Nephrol 2012, 78:328-331. 10.5414/CN107205, 22981036.
24. Fukushima H, Hashizume T, Morita Y, Tanaka J, Azuma K, Mizumoto Y, Kaneno M, Matsuura M, Konma K, Kitani T. Clinical experiences in Sakai City Hospital during the massive outbreak of enterohemorrhagic Escherichia coli O157 infections in Sakai City, 1996. Pediatr Int 1999, 41:213-217. 10.1046/j.1442-200X.1999.4121041.x, 10221032.
25. Kunzendorf U, Karch H, Werber D, Haller H. Recent outbreak of hemolytic uremic syndrome in Germany. Kidney Int 2011, 80:900-902. 10.1038/ki.2011.323, 21997502.
26. Lopez EL, Contrini MM, Glatstein E, Ayala SG, Santoro R, Ezcurra G, Teplitz E, Matsumoto Y, Sato H, Sakai K, Katsuura Y, Hoshide S, Morita T, Harning R, Brookman S. An epidemiologic surveillance of Shiga-like toxin-producing Escherichia coli infection in Argentinean children: risk factors and serum Shiga-like toxin 2 values. Pediatr Infect Dis J 2012, 31:20-24. 10.1097/INF.0b013e31822ea6cf, 21829137.
27. Rivero MA, Passucci JA, Rodriguez EM, Signorini ML, Tarabla HD, Parma AE. Factors associated with sporadic verotoxigenic Escherichia coli infection in children with diarrhea from the Central Eastern Area of Argentina. Foodborne Pathog Dis 2011, 8:901-906. 10.1089/fpd.2010.0800, 21492023.
28. Crim SM, Iwamoto M, Huang JY, Griffin PM, Gilliss D, Cronquist AB, Cartter M, Tobin-D'Angelo M, Blythe D, Smith K, Lathrop S, Zansky S, Cieslak PR, Dunn J, Holt KG, Lance S, Tauxe R, Henao OL. Incidence and trends of infection with pathogens transmitted commonly through food - foodborne diseases active surveillance network, 10 u.s. Sites, 2006-2013. MMWR Morb Mortal Wkly Rep 2014, 63:328-332.
29. Okuda T, Tokuda N, Numata S, Ito M, Ohta M, Kawamura K, Wiels J, Urano T, Tajima O, Furukawa K, Furukawa K. Targeted disruption of Gb3/CD77 synthase gene resulted in the complete deletion of globo-series glycosphingolipids and loss of sensitivity to verotoxins. J Biol Chem 2006, 281:10230-10235. 10.1074/jbc. M600057200, 16476743.
30. Keepers TR, Psotka MA, Gross LK, Obrig TG. A murine model of HUS: Shiga toxin with lipopolysaccharide mimics the renal damage and physiologic response of human disease. J Am Soc Nephrol 2006, 17:3404-3414. 10.1681/ASN.2006050419, 17082244.
31. Iskander K, Osuchowski M, Stearns-Kurosawa D, Kurosawa S, Stepien D, Valentine C, Remick D. Sepsis: multiple abnormalities, heterogenous responses, evolving understanding. Physiol Rev 2013, in press.
32. Noris M, Mescia F, Remuzzi G. STEC-HUS, atypical HUS and TTP are all diseases of complement activation. Nat Rev Nephrol 2012, 8:622-633. 10.1038/nrneph.2012.195, 22986360.
33. Delmas Y, Vendrely B, Clouzeau B, Bachir H, Bui HN, Lacraz A, Helou S, Bordes C, Reffet A, Llanas B, Skopinski S, Rolland P, Gruson D, Combe C. Outbreak of Escherichia coli O104:H4 haemolytic uraemic syndrome in France: outcome with eculizumab. Nephrol Dial Transplant 2014, 29:565-572. 10.1093/ndt/gft470, 3938298, 24293658.
34. Wong CS, Mooney JC, Brandt JR, Staples AO, Jelacic S, Boster DR, Watkins SL, Tarr PI. Risk factors for the hemolytic uremic syndrome in children infected with Escherichia coli O157:H7: a multivariable analysis. Clin Infect Dis 2012, 55:33-41. 10.1093/cid/cis299, 3493180, 22431799.
35. Stearns-Kurosawa DJ, Collins V, Freeman S, Tesh VL, Kurosawa S. Distinct physiologic and inflammatory responses elicited in baboons after challenge with Shiga toxin type 1 or 2 from enterohemorrhagic Escherichia coli. Infect Immun 2010, 78:2497-2504. 10.1128/IAI.01435-09, 2876564, 20308301.
36. Stearns-Kurosawa DJ, Oh SY, Cherla RP, Lee MS, Tesh VL, Papin J, Henderson J, Kurosawa S. Distinct renal pathology and a chemotactic phenotype after enterohemorrhagic Escherichia coli Shiga toxins in non-human primate models of hemolytic uremic syndrome. Am J Pathol 2013, 182:1227-1238. 10.1016/j.ajpath.2012.12.026, 3620421, 23402998.
37. Stearns-Kurosawa DJ, Collins V, Freeman S, Debord D, Nishikawa K, Oh SY, Leibowitz CS, Kurosawa S. Rescue from lethal Shiga toxin 2-induced renal failure with a cell-permeable peptide. Pediatr Nephrol 2011, 26:2031-2039. 10.1007/s00467-011-1913-y, 3179571, 21603905.
38. Lee BC, Mayer CL, Leibowitz CS, Stearns-Kurosawa DJ, Kurosawa S. Quiescent complement in nonhuman primates during E. coli Shiga toxin-induced hemolytic uremic syndrome and thrombotic microangiopathy. Blood 2013, 122:803-806. 10.1182/blood-2013-03-490060, 3731933, 23733336.
39. Mallick EM, McBee ME, Vanguri VK, Melton-Celsa AR, Schlieper K, Karalius BJ, O'Brien AD, Butterton JR, Leong JM, Schauer DB. A novel murine infection model for Shiga toxin-producing Escherichia coli. J Clin Invest 2012, 122:4012-4024. 10.1172/JCI62746, 3484439, 23041631.
40. Silasi-Mansat R, Zhu H, Popescu NI, Peer G, Sfyroera G, Magotti P, Ivanciu L, Lupu C, Mollnes TE, Taylor FB, Kinasewitz G, Lambris JD, Lupu F. Complement inhibition decreases the procoagulant response and confers organ protection in a baboon model of Escherichia coli sepsis. Blood 2010, 116:1002-1010. 10.1182/blood-2010-02-269746, 2924221, 20466856.
41. Burk AM, Martin M, Flierl MA, Rittirsch D, Helm M, Lampl L, Bruckner U, Stahl GL, Blom AM, Perl M, Gebhard F, Huber-Lang M. Early complementopathy after multiple injuries in humans. Shock 2012, 37:348-354. 10.1097/SHK.0b013e3182471795, 3306539, 22258234.
42. Muroya T, Kannan L, Ghiran IC, Shevkoplyas SS, Paz Z, Tsokos M, Dalle Lucca JJ, Shapiro NI, Tsokos GC. C4d deposits on the surface of RBCs in trauma patients and interferes with their function. Crit Care Med 2014, 42:e364-e372. 10.1097/CCM.0000000000000231, 24448198.
43. Taylor FB. Staging of the pathophysiologic responses of the primate microvasculature to Escherichia coli and endotoxin: examination of the elements of the compensated response and their links to the corresponding uncompensated lethal variants. Crit Care Med 2001, 29:S78-S89. 10.1097/00003246-200107001-00026, 11445739.
44. Lippi G, Ippolito L, Cervellin G. Disseminated intravascular coagulation in burn injury. Semin Thromb Hemost 2010, 36:429-436. 10.1055/s-0030-1254051, 20614394.
45. Ward PA. Role of C5 activation products in sepsis. ScientificWorld J 2010, 10:2395-2402.
46. Sillesen M, Rasmussen LS, Jin G, Jepsen CH, Imam A, Hwabejire JO, Halaweish I, DeMoya M, Velmahos G, Johansson PI, Alam HB. Assessment of coagulopathy, endothelial injury, and inflammation after traumatic brain injury and hemorrhage in a porcine model. J Trauma Acute Care Surg 2014, 76:12-19. 10.1097/TA.0b013e3182aaa675, 24368352.
47. Peterson SL, Anderson AJ. Complement and spinal cord injury: traditional and non-traditional aspects of complement cascade function in the injured spinal cord microenvironment. Exp Neurol 2014, 258C:35-47.
48. Fluiter K, Opperhuizen AL, Morgan BP, Baas F, Ramaglia V. Inhibition of membrane attack complex of the complement system reduces secondary neuroaxonal loss and promotes neurologic recovery after traumatic injury in mice. J Immunol 2014, 192:2339-2348. 10.4049/jimmunol.1302793, 24489093.
49. Neher MD, Rich MC, Keene CN, Weckbach S, Bolden AL, Losacco JT, Patane J, Flierl MA, Kulik L, Holers VM, Stahel PF. Deficiency of complement receptors CR2/CR1 in Cr2(-)/(-) mice reduces the extent of secondary brain damage after closed head injury. J Neuroinflammation 2014, 11:95. 10.1186/1742-2094-11-95, 4050415, 24885042.
50. Riedl M, Fakhouri F, Le Quintrec M, Noone DG, Jungraithmayr TC, Fremeaux-Bacchi V, Licht C. Spectrum of complement-mediated thrombotic microangiopathies: pathogenetic insights identifying novel treatment approaches. Semin Thromb Hemost 2014, 40:444-464. 10.1055/s-0034-1376153, 24911558.
51. Laudes IJ, Chu JC, Sikranth S, Huber-Lang M, Guo RF, Riedemann N, Sarma JV, Schmaier AH, Ward PA. Anti-c5a ameliorates coagulation/fibrinolytic protein changes in a rat model of sepsis. Am J Pathol 2002, 160:1867-1875. 10.1016/S0002-9440(10)61133-9, 1850866, 12000738.
52. Jansen PM, Eisele B, de Jong IW, Chang A, Delvos U, Taylor FB, Hack CE. Effect of C1 inhibitor on inflammatory and physiologic response patterns in primates suffering from lethal septic shock. J Immunol 1998, 160:475-484.
53. Atkinson C, Song H, Lu B, Qiao F, Burns TA, Holers VM, Tsokos GC, Tomlinson S. Targeted complement inhibition by C3d recognition ameliorates tissue injury without apparent increase in susceptibility to infection. J Clin Invest 2005, 115:2444-2453. 10.1172/JCI25208, 1190375, 16127466.
54. Fridkis-Hareli M, Storek M, Mazsaroff I, Risitano A, Lundberg AS, Horvath CJ, Holers VM. Design and development of TT30, a novel C3d-targeted C3/C5 convertase inhibitor for treatment of human complement alternative pathway-mediated diseases. Blood 2011, 118:4705-4713. 10.1182/blood-2011-06-359646, 3208285, 21860027.
55. DiLillo DJ, Pawluczkowycz AW, Peng W, Kennedy AD, Beum PV, Lindorfer MA, Taylor RP. Selective and efficient inhibition of the alternative pathway of complement by a mAb that recognizes C3b/iC3b. Mol Immunol 2006, 43:1010-1019. 10.1016/j.molimm.2005.05.003, 15961157.